vs
AtriCure, Inc.（ATRC）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是AtriCure, Inc.的1.1倍（$151.1M vs $140.5M），AtriCure, Inc.同比增速更快（13.1% vs 3.6%），AtriCure, Inc.自由现金流更多（$18.4M vs $12.3M），过去两年AtriCure, Inc.的营收复合增速更高（13.6% vs 5.1%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
ATRC vs RGR — 直观对比
营收规模更大
RGR
是对方的1.1倍
$140.5M
营收增速更快
ATRC
高出9.4%
3.6%
自由现金流更多
ATRC
多$6.1M
$12.3M
两年增速更快
ATRC
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.5M | $151.1M |
| 净利润 | — | — |
| 毛利率 | 75.0% | 17.8% |
| 营业利润率 | 1.8% | 2.3% |
| 净利率 | — | — |
| 营收同比 | 13.1% | 3.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.04 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCRGR
| Q4 25 | $140.5M | $151.1M | ||
| Q3 25 | $134.3M | $126.8M | ||
| Q2 25 | $136.1M | $132.5M | ||
| Q1 25 | $123.6M | $135.7M | ||
| Q4 24 | $124.3M | $145.8M | ||
| Q3 24 | $115.9M | $122.3M | ||
| Q2 24 | $116.3M | $130.8M | ||
| Q1 24 | $108.9M | $136.8M |
净利润ATRCRGR
| Q4 25 | — | — | ||
| Q3 25 | $-267.0K | $1.6M | ||
| Q2 25 | $-6.2M | $-17.2M | ||
| Q1 25 | $-6.7M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-7.9M | $4.7M | ||
| Q2 24 | $-8.0M | $8.3M | ||
| Q1 24 | $-13.3M | $7.1M |
毛利率ATRCRGR
| Q4 25 | 75.0% | 17.8% | ||
| Q3 25 | 75.5% | 15.1% | ||
| Q2 25 | 74.5% | 3.9% | ||
| Q1 25 | 74.9% | 22.0% | ||
| Q4 24 | 74.5% | 22.8% | ||
| Q3 24 | 74.9% | 18.5% | ||
| Q2 24 | 74.7% | 22.3% | ||
| Q1 24 | 74.7% | 21.5% |
营业利润率ATRCRGR
| Q4 25 | 1.8% | 2.3% | ||
| Q3 25 | 0.2% | -2.7% | ||
| Q2 25 | -4.5% | -15.6% | ||
| Q1 25 | -4.8% | 6.2% | ||
| Q4 24 | -11.7% | 7.8% | ||
| Q3 24 | -6.4% | 3.1% | ||
| Q2 24 | -6.2% | 6.9% | ||
| Q1 24 | -10.0% | 5.5% |
净利率ATRCRGR
| Q4 25 | — | — | ||
| Q3 25 | -0.2% | 1.2% | ||
| Q2 25 | -4.5% | -13.0% | ||
| Q1 25 | -5.5% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.8% | 3.9% | ||
| Q2 24 | -6.9% | 6.3% | ||
| Q1 24 | -12.2% | 5.2% |
每股收益（稀释后）ATRCRGR
| Q4 25 | $0.04 | $0.22 | ||
| Q3 25 | $-0.01 | $0.10 | ||
| Q2 25 | $-0.13 | $-1.05 | ||
| Q1 25 | $-0.14 | $0.46 | ||
| Q4 24 | $-0.33 | $0.62 | ||
| Q3 24 | $-0.17 | $0.28 | ||
| Q2 24 | $-0.17 | $0.47 | ||
| Q1 24 | $-0.28 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.4M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $491.9M | $283.8M |
| 总资产 | $654.2M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCRGR
| Q4 25 | $167.4M | $92.5M | ||
| Q3 25 | $147.9M | $80.8M | ||
| Q2 25 | $117.8M | $101.4M | ||
| Q1 25 | $99.9M | $108.3M | ||
| Q4 24 | $122.7M | $105.5M | ||
| Q3 24 | $130.3M | $96.0M | ||
| Q2 24 | $114.0M | $105.6M | ||
| Q1 24 | $106.0M | $115.3M |
总债务ATRCRGR
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — | ||
| Q1 24 | $61.9M | — |
股东权益ATRCRGR
| Q4 25 | $491.9M | $283.8M | ||
| Q3 25 | $476.5M | $279.6M | ||
| Q2 25 | $464.5M | $289.3M | ||
| Q1 25 | $454.6M | $321.5M | ||
| Q4 24 | $461.0M | $319.6M | ||
| Q3 24 | $465.0M | $314.9M | ||
| Q2 24 | $462.1M | $321.5M | ||
| Q1 24 | $456.3M | $332.0M |
总资产ATRCRGR
| Q4 25 | $654.2M | $342.0M | ||
| Q3 25 | $635.4M | $342.3M | ||
| Q2 25 | $608.8M | $349.5M | ||
| Q1 25 | $591.6M | $379.0M | ||
| Q4 24 | $609.3M | $384.0M | ||
| Q3 24 | $615.1M | $373.5M | ||
| Q2 24 | $597.3M | $376.7M | ||
| Q1 24 | $591.6M | $385.0M |
负债/权益比ATRCRGR
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $20.0M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $18.4M | $12.3M |
| 自由现金流率自由现金流/营收 | 13.1% | 8.2% |
| 资本支出强度资本支出/营收 | 1.1% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $48.3M | $38.5M |
8季度趋势，按日历期对齐
经营现金流ATRCRGR
| Q4 25 | $20.0M | $15.5M | ||
| Q3 25 | $26.7M | $12.9M | ||
| Q2 25 | $21.6M | $14.7M | ||
| Q1 25 | $-11.0M | $11.1M | ||
| Q4 24 | $5.8M | $20.0M | ||
| Q3 24 | $20.0M | $9.4M | ||
| Q2 24 | $7.4M | $18.7M | ||
| Q1 24 | $-21.0M | $7.3M |
自由现金流ATRCRGR
| Q4 25 | $18.4M | $12.3M | ||
| Q3 25 | $24.1M | $7.0M | ||
| Q2 25 | $19.0M | $9.1M | ||
| Q1 25 | $-13.2M | $10.0M | ||
| Q4 24 | $3.1M | $16.4M | ||
| Q3 24 | $16.4M | $2.6M | ||
| Q2 24 | $5.0M | $10.1M | ||
| Q1 24 | $-23.8M | $5.6M |
自由现金流率ATRCRGR
| Q4 25 | 13.1% | 8.2% | ||
| Q3 25 | 18.0% | 5.5% | ||
| Q2 25 | 13.9% | 6.9% | ||
| Q1 25 | -10.7% | 7.4% | ||
| Q4 24 | 2.5% | 11.2% | ||
| Q3 24 | 14.1% | 2.1% | ||
| Q2 24 | 4.3% | 7.7% | ||
| Q1 24 | -21.9% | 4.1% |
资本支出强度ATRCRGR
| Q4 25 | 1.1% | 2.1% | ||
| Q3 25 | 1.9% | 4.6% | ||
| Q2 25 | 2.0% | 4.2% | ||
| Q1 25 | 1.8% | 0.8% | ||
| Q4 24 | 2.2% | 2.5% | ||
| Q3 24 | 3.1% | 5.5% | ||
| Q2 24 | 2.1% | 6.6% | ||
| Q1 24 | 2.5% | 1.3% |
现金转化率ATRCRGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage Management | $45.5M | 32% |
| Openheart | $38.5M | 27% |
| Other | $26.2M | 19% |
| Pain Management | $22.6M | 16% |
| Minimally Invasive | $7.7M | 6% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
